|
1
|
Romero I and Bast RC Jr: Minireview: human
ovarian cancer: biology, current management, and paths to
personalizing therapy. Endocrinology. 153:1593–1602. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Choi JH, Wong AS, Huang HF and Leung PC:
Gonadotropins and ovarian cancer. Endocr Rev. 28:440–461. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tummala MK and McGuire WP: Recurrent
ovarian cancer. Clin Adv Hematol Oncol. 3:723–736. 2005.
|
|
4
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
5
|
Cullen BR: MicroRNAs as mediators of viral
evasion of the immune system. Nat Immunol. 14:205–210. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wei Y, Schober A and Weber C: Pathogenic
arterial remodeling: the good and bad of microRNAs. Am J Physiol
Heart Circ Physiol. 304:H1050–H1059. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Itesako T, Seki N, Yoshino H, et al: The
microRNA expression signature of bladder cancer by deep sequencing:
the functional significance of the miR-195/497 cluster. PLoS One.
9:e843112014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu YZ, Xi QH, Ge WL and Zhang XQ:
Identification of serum microRNA-21 as a biomarker for early
detection and prognosis in human epithelial ovarian cancer. Asian
Pac J Cancer Prev. 14:1057–1060. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Laddha SV, Nayak S, Paul D, et al:
Genome-wide analysis reveals downregulation of miR-379/miR-656
cluster in human cancers. Biol Direct. 8:102013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tang H, Yao L, Tao X, et al: miR-9
functions as a tumor suppressor in ovarian serous carcinoma by
targeting TLN1. Int J Mol Med. 32:381–388. 2013.PubMed/NCBI
|
|
11
|
Cao J, Cai J, Huang D, et al: miR-335
represents an invasion suppressor gene in ovarian cancer by
targeting Bcl-w. Oncol Rep. 30:701–706. 2013.PubMed/NCBI
|
|
12
|
Shao X, Mei W, Weng W, et al: Mir-375
enhances ruthenium-derived compound Rawq01 induced cell death in
human ovarian cancer. Int J Clin Exp Pathol. 6:1095–1102.
2013.PubMed/NCBI
|
|
13
|
Nakayama I, Shibazaki M, Yashima-Abo A, et
al: Loss of HOXD10 expression induced by upregulation of miR-10b
accelerates the migration and invasion activities of ovarian cancer
cells. Int J Oncol. 43:63–71. 2013.PubMed/NCBI
|
|
14
|
Yang Q, Zhang C, Huang B, et al:
Downregulation of microRNA-206 is a potent prognostic marker for
patients with gastric cancer. Eur J Gastroenterol Hepatol.
25:953–957. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Y, Hong F and Yu Z: Decreased
expression of microRNA-206 in breast cancer and its association
with disease characteristics and patient survival. J Int Med Res.
41:596–602. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Parasramka MA, Dashwood WM, Wang R, et al:
A role for low-abundance miRNAs in colon cancer: the
miR-206/Krüppel-like factor 4 (KLF4) axis. Clin Epigenetics.
4:162012.PubMed/NCBI
|
|
17
|
Guo R, Wu Q, Liu F and Wang Y: Description
of the CD133+ subpopulation of the human ovarian cancer
cell line OVCAR3. Oncol Rep. 25:141–146. 2011.
|
|
18
|
Adams BD, Furneaux H and White BA: The
micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen
receptor-alpha (ERalpha) and represses ERalpha messenger RNA and
protein expression in breast cancer cell lines. Mol Endocrinol.
21:1132–1147. 2007. View Article : Google Scholar
|
|
19
|
Chen X, Yan Q, Li S, et al: Expression of
the tumor suppressor miR-206 is associated with cellular
proliferative inhibition and impairs invasion in ERα-positive
endometrioid adenocarcinoma. Cancer Lett. 314:41–53.
2012.PubMed/NCBI
|
|
20
|
Pan Q, Luo X, Toloubeydokhti T and Chegini
N: The expression profile of micro-RNA in endometrium and
endometriosis and the influence of ovarian steroids on their
expression. Mol Hum Reprod. 13:797–806. 2007. View Article : Google Scholar
|
|
21
|
Park MA, Hwang KA, Lee HR, Yi BR, Jeung EB
and Choi KC: Benzophenone-1 stimulated the growth of BG-1 ovarian
cancer cells by cell cycle regulation via an estrogen receptor
alpha-mediated signaling pathway in cellular and xenograft mouse
models. Toxicology. 305:41–48. 2013. View Article : Google Scholar
|
|
22
|
Kimura A, Ohmichi M, Kawagoe J, et al:
Induction of hTERT expression and phosphorylation by estrogen via
Akt cascade in human ovarian cancer cell lines. Oncogene.
23:4505–4515. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhu J, Lu X, Hua KQ, Sun H, Yu YH and Feng
YJ: Oestrogen receptor α mediates 17β-estradiol enhancement of
ovarian cancer cell motility through up-regulation of survivin
expression. Arch Gynecol Obstet. 286:729–737. 2012.
|
|
24
|
Merlo S and Sortino MA: Estrogen activates
matrix metalloproteinases-2 and −9 to increase beta amyloid
degradation. Mol Cell Neurosci. 49:423–429. 2012.
|
|
25
|
Shuman Moss LA, Jensen-Taubman S and
Stetler-Stevenson WG: Matrix metalloproteinases: changing roles in
tumor progression and metastasis. Am J Pathol. 181:1895–1899.
2012.PubMed/NCBI
|
|
26
|
Macquarrie KL, Yao Z, Young JM, Cao Y and
Tapscott SJ: miR-206 integrates multiple components of
differentiation pathways to control the transition from growth to
differentiation in rhabdomyosarcoma cells. Skelet Muscle. 2:72012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang T, Liu M, Wang C, Lin C, Sun Y and
Jin D: Down-regulation of MiR-206 promotes proliferation and
invasion of laryngeal cancer by regulating VEGF expression.
Anticancer Res. 31:3859–3863. 2011.PubMed/NCBI
|
|
28
|
Artacho-Cordón F, Rios-Arrabal S, Lara PC,
Artacho-Cordón A, Calvente I and Núñez MI: Matrix
metalloproteinases: potential therapy to prevent the development of
second malignancies after breast radiotherapy. Surg Oncol.
21:e143–e151. 2012.PubMed/NCBI
|
